Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.
about
Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigensKASL clinical practice guidelines: management of chronic hepatitis BChronic Hepatitis B with Spontaneous Severe Acute ExacerbationThe Role of Oxidative Stress and Antioxidants in Liver DiseasesAcute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis BProminent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis CImmunology of hepatitis B virus and hepatitis C virus infectionCurrent role of transient elastography in the management of chronic hepatitis B patientsAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production.No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infectionProtection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12.Intrahepatic T cells in hepatitis B: viral control versus liver cell injury.Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapyDeficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation.Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbationVirus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels.Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversionNovel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in Balb/c mice.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.The serology of chronic hepatitis B infection revisited.Long-term prognosis of chronic hepatitis B virus infection in the childhood.The level of viral antigen presented by hepatocytes influences CD8 T-cell function.Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens.Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.Humoral and cellular immunogenecity of DNA vaccine based on hepatitis B core gene in rhesus monkeysImmune pathogenesis of hepatocellular carcinoma.The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma.Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liverImmunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitisMolecular characteristics and stages of chronic hepatitis B virus infectionPeripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load
P2860
Q24673500-B4C0FF85-7076-468E-82BA-66BF471AED45Q26752475-BC7E9A04-AA64-4E73-A04E-8AEF7D848FBCQ26772036-C5555BFA-109D-4D3E-82A2-7A82E1F2D5E9Q26779146-89459955-DE44-4143-8A67-27443A3404DBQ27022622-6600C2E6-E5E2-4766-A021-E12447A2BCC0Q27473528-9E8ECF0D-7F0B-484E-AE7B-C8E8163B18F9Q29618957-58D7ED9E-02E0-4F37-BEE6-0482266AB18FQ30358894-72ED2A13-91CB-46D2-A5BC-36C4B320762CQ30391932-B6E9449D-E2B8-4BFF-99F0-724A80F6F458Q31906856-B0B123DA-7510-4CD5-AFC7-04C7C3B1031CQ33676594-4156B719-9423-437E-8BFC-4601EE0E862CQ33787525-D60FFC53-02E0-4610-BCAC-3A59C7AB0B2FQ33845287-D3C3C22A-AB19-4822-8C8D-E51DB5662F1FQ33894481-ADF89D66-45B7-470E-AB71-1948B045D2CCQ34151071-45B45325-7693-4320-B692-788C4F906400Q34330734-260363A7-696C-447D-9140-4B909292AB33Q34365631-8BD6C050-19BA-4FE8-B20F-AD2D61171F64Q34552034-A0B8B3D0-993C-4A06-8031-8F3935FEFA95Q34553545-B1CA1728-AD9C-4BF3-9344-63039C37D0E9Q34764269-5F92AFEC-66C7-40B8-AAAF-4AA6A39F0039Q34779745-1010D04A-2CB7-456E-ABEC-AB13C88A1CC5Q35076712-707BF658-7E6A-4D48-8836-4B1187544A15Q35092342-B2914C22-8082-4DAD-9530-7DC93EB5042AQ35435556-4BCE8C65-7161-4566-9219-EFD55FE8B3FFQ35595469-639DE97E-AFF3-4BE7-A2D0-ECE19569981CQ35597901-87CA270A-18B0-4D04-80CA-114FDFBA8D40Q35610765-4DD5DCE6-C8E7-4F1D-BDB7-96D8C2D354F4Q35712564-452F2121-0BCE-41FA-9FAF-162C7D76D4A4Q35784981-636FAD87-C125-40F4-82F8-76A231E419A0Q35882104-DFEB0BCE-1108-4522-ACC3-C38EEA2C7E88Q36099102-11C929DC-DE33-4AC3-A28D-795FACC75E7FQ36153966-56E42A3C-DD4F-47F1-BFEE-5EEE1F2798EFQ36267204-04C74D6F-27E0-456C-8EBE-DA89EF886BC5Q36397263-976A90FC-CDCD-4B3F-877F-915EC30FB9F8Q36401448-78C3D1B9-7BA3-4CDD-AF33-9A00FECB11AEQ36419017-17CCD2F4-009B-4659-9D5E-7621D7E8979FQ36871557-03059F11-7A80-439C-BBF7-B315FC68EE43Q37109088-6E3E8416-EC17-44AC-8663-FFB193F611CFQ37250341-B79BDD77-DE8A-4A7F-B3C1-BD6C99DF138CQ37267440-DEE7BC27-EFC6-476F-9D1F-3C2B6EA603B8
P2860
Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@ast
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@en
type
label
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@ast
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@en
prefLabel
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@ast
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@en
P2093
P2860
P356
P1476
Acute exacerbations of chronic ...... is B e antigen seroconversion.
@en
P2093
P2860
P356
10.1172/JCI115590
P407
P577
1992-01-01T00:00:00Z